Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 53

1.

HtrA1 Mediated Intracellular Effects on Tubulin Using a Polarized RPE Disease Model.

Melo E, Oertle P, Trepp C, Meistermann H, Burgoyne T, Sborgi L, Cabrera AC, Chen CY, Hoflack JC, Kam-Thong T, Schmucki R, Badi L, Flint N, Ghiani ZE, Delobel F, Stucki C, Gromo G, Einhaus A, Hornsperger B, Golling S, Siebourg-Polster J, Gerber F, Bohrmann B, Futter C, Dunkley T, Hiller S, Schilling O, Enzmann V, Fauser S, Plodinec M, Iacone R.

EBioMedicine. 2018 Jan;27:258-274. doi: 10.1016/j.ebiom.2017.12.011. Epub 2017 Dec 13.

2.

Disease modeling and phenotypic drug screening for diabetic cardiomyopathy using human induced pluripotent stem cells.

Drawnel FM, Boccardo S, Prummer M, Delobel F, Graff A, Weber M, Gérard R, Badi L, Kam-Thong T, Bu L, Jiang X, Hoflack JC, Kiialainen A, Jeworutzki E, Aoyama N, Carlson C, Burcin M, Gromo G, Boehringer M, Stahlberg H, Hall BJ, Magnone MC, Kolaja K, Chien KR, Bailly J, Iacone R.

Cell Rep. 2014 Nov 6;9(3):810-21. doi: 10.1016/j.celrep.2014.09.055. Epub 2014 Oct 30.

3.

Cardiovascular drug discovery: a perspective from a research-based pharmaceutical company.

Gromo G, Mann J, Fitzgerald JD.

Cold Spring Harb Perspect Med. 2014 Jun 2;4(6). pii: a014092. doi: 10.1101/cshperspect.a014092. Review.

4.

Selective elimination of human pluripotent stem cells by an oleate synthesis inhibitor discovered in a high-throughput screen.

Ben-David U, Gan QF, Golan-Lev T, Arora P, Yanuka O, Oren YS, Leikin-Frenkel A, Graf M, Garippa R, Boehringer M, Gromo G, Benvenisty N.

Cell Stem Cell. 2013 Feb 7;12(2):167-79. doi: 10.1016/j.stem.2012.11.015. Epub 2013 Jan 11.

5.

A guide to drug discovery: Target selection in drug discovery.

Knowles J, Gromo G.

Nat Rev Drug Discov. 2003 Jan;2(1):63-9. Review.

PMID:
12509760
6.

Increased protein kinase C activity and expression of Ca2+-sensitive isoforms in the failing human heart.

Bowling N, Walsh RA, Song G, Estridge T, Sandusky GE, Fouts RL, Mintze K, Pickard T, Roden R, Bristow MR, Sabbah HN, Mizrahi JL, Gromo G, King GL, Vlahos CJ.

Circulation. 1999 Jan 26;99(3):384-91.

PMID:
9918525
7.

Effect of partially modified retro-inverso analogues derived from C-reactive protein on the induction of nitric oxide synthesis in peritoneal macrophages.

Arcoleo F, Milano S, D'Agostino P, Misiano G, Cappelletti S, Gromo G, Marcucci F, Leoni F, Cillari E.

Br J Pharmacol. 1997 Apr;120(7):1383-9.

8.

Rational design of a new C-myristylamido peptide exerting potent and selective PKC inhibitory activity.

Zaliani A, Gromo G, Pinori M, Mascagni P.

Drug Des Discov. 1996 Apr;13(3-4):63-74.

PMID:
8874044
9.

Different cytotoxic activity and intracellular fate of an anti-CD5-momordin immunotoxin in normal compared to tumour cells.

Porro G, Lento P, Marcucci F, Gromo G, Modena D.

Cancer Immunol Immunother. 1995 Apr;40(4):213-8.

PMID:
7538448
10.

Expression in Escherichia coli, purification and functional activity of recombinant human chaperonin 10.

Legname G, Fossati G, Gromo G, Monzini N, Marcucci F, Modena D.

FEBS Lett. 1995 Mar 20;361(2-3):211-4.

11.

New antianginal nitro esters with reduced hypotensive activity. Synthesis and pharmacological evaluation of 3-[(nitrooxy)alkyl]-2H-1,3-benzoxazin-4(3H)-ones.

Benedini F, Bertolini G, Cereda R, Donà G, Gromo G, Levi S, Mizrahi J, Sala A.

J Med Chem. 1995 Jan 6;38(1):130-6.

PMID:
7837224
12.

Cochaperonins are histone-binding proteins.

Bonardi MA, Giovanetti E, Legname G, Fossati G, Porro G, Gromo G, Modena D, Marcucci F.

Biochem Biophys Res Commun. 1995 Jan 5;206(1):260-5.

PMID:
7818529
13.

Heterologous expression, purification, activity and conformational studies of different forms of dianthin 30.

Legname G, Fossati G, Monzini N, Gromo G, Marcucci F, Mascagni P, Modena D.

Biomed Pept Proteins Nucleic Acids. 1995;1(2):61-8.

PMID:
9346855
14.

Protective effect of the nitrate ester ITF 296 against methacholine-induced myocardial ischemia in the anesthetized rat.

Cereda R, Bergamaschi M, Agozzino S, Bravi F, Gromo G, Mascheroni G, Mizrahi J.

J Cardiovasc Pharmacol. 1995;26 Suppl 4:S37-43.

PMID:
8839225
15.

The new nitroderivative ITF 296 improves collateral blood flow in a canine model of coronary thrombosis.

Trivella MG, Barsotti G, Cereda R, Chiaverini F, Gromo G, L'Abbate A, Magnozzi D, Mizrahi J, Pelosi G, Taddei L, et al.

J Cardiovasc Pharmacol. 1995;26 Suppl 4:S31-6.

PMID:
8839224
16.

Effect of the new nitrate ester ITF 296 on coronary and systemic hemodynamics in the conscious dog: comparison with nitroglycerin and nicorandil.

Ueno A, Bergamaschi M, Gromo G, Nonaka K, Mizrahi J.

J Cardiovasc Pharmacol. 1995;26 Suppl 4:S13-20.

PMID:
8839221
17.

The discovery of a new organic nitrate: an overview.

Benedini F, Bertolini G, Gromo G, Mizrahi J, Sala A.

J Cardiovasc Pharmacol. 1995;26 Suppl 4:S1-5. Review.

PMID:
8839219
18.

Identification and cloning of human chaperonin 10 homologue.

Monzini N, Legname G, Marcucci F, Gromo G, Modena D.

Biochim Biophys Acta. 1994 Aug 2;1218(3):478-80.

PMID:
7914093
19.

The macrophage-activating tetrapeptide tuftsin induces nitric oxide synthesis and stimulates murine macrophages to kill Leishmania parasites in vitro.

Cillari E, Arcoleo F, Dieli M, D'Agostino R, Gromo G, Leoni F, Milano S.

Infect Immun. 1994 Jun;62(6):2649-52.

20.

Arthritogenic potential of the 65 kDa stress protein--an experimental model.

Winrow VR, Ragno S, Morris CJ, Colston MJ, Mascagni P, Leoni F, Gromo G, Coates AR, Blake DR.

Ann Rheum Dis. 1994 Mar;53(3):197-201.

21.

Involvement of multiple protein kinases in CD3-mediated activation of human T lymphocytes.

Chiaffarino F, Biffi M, Luciano A, Gromo G, Leoni F.

Cell Immunol. 1994 Jan;153(1):39-51.

PMID:
7904541
22.
23.

Expression and activity of pre-dianthin 30 and dianthin 30.

Legname G, Gromo G, Lord JM, Monzini N, Modena D.

Biochem Biophys Res Commun. 1993 May 14;192(3):1230-7. Erratum in: Biochem Biophys Res Commun 1993 Aug 31;195(1):506.

PMID:
8507195
24.

In vitro and in vivo properties of an anti-CD5-momordin immunotoxin on normal and neoplastic T lymphocytes.

Porro G, Bolognesi A, Caretto P, Gromo G, Lento P, Mistza G, Sciumbata T, Stirpe F, Modena D.

Cancer Immunol Immunother. 1993 May;36(5):346-50.

PMID:
7682894
25.

A comparison of anti-lymphocyte immunotoxins containing different ribosome-inactivating proteins and antibodies.

Bolognesi A, Tazzari PL, Tassi C, Gromo G, Gobbi M, Stirpe F.

Clin Exp Immunol. 1992 Sep;89(3):341-6.

26.

Activation of rat T cells in vitro and in vivo with a bispecific (anti-TCR x anti-CD2) F(ab')2 derivative.

Bonardi MA, Tutt A, Gromo G, Modena D, Glennie M.

Pharmacol Res. 1992 Sep;26 Suppl 2:139-40. No abstract available.

PMID:
1409281
27.

Modulation of IL-2, IFN-gamma, TNF-alpha and IL-4 production in mice of different ages by thymopentin.

Cillari E, Milano S, Perego R, Gromo G, D'Agostino R, Arcoleo F, Dieli M.

Int J Immunopharmacol. 1992 Aug;14(6):1029-35.

PMID:
1428357
28.

Thymopentin reduces the susceptibility of aged mice to cutaneous leishmaniasis by modulating CD4 T-cell subsets.

Cillari E, Milano S, Dieli M, Arcoleo F, Perego R, Leoni F, Gromo G, Severn A, Liew FY.

Immunology. 1992 Jul;76(3):362-6.

29.

Initial experience in treating human lymphoma with a combination of bispecific antibody and saporin.

Bonardi MA, Bell A, French RR, Gromo G, Hamblin T, Modena D, Tutt AL, Glennie MJ.

Int J Cancer Suppl. 1992;7:73-7.

PMID:
1428411
30.

Nucleotide sequence of cDNA coding for dianthin 30, a ribosome inactivating protein from Dianthus caryophyllus.

Legname G, Bellosta P, Gromo G, Modena D, Keen JN, Roberts LM, Lord JM.

Biochim Biophys Acta. 1991 Aug 27;1090(1):119-22. Erratum in: Biochim Biophys Acta 1991 Nov 11;1090(3):355.

PMID:
1840496
31.

Dysregulated release and degradation of insulin during mononuclear cell-induced beta-cell lysis in HIT cells.

Robertson RP, Gromo G, Zhang HJ, Walseth TF, Inverardi L.

Diabetes. 1991 Apr;40(4):449-56.

PMID:
1672658
32.

A "minimal signal-stepwise activation" analysis of functional maturation of T lymphocytes.

Bach FH, Geller RL, Nelson PJ, Panzer S, Gromo G, Benfield MR, Inverardi L, Podack ER, Witson JC, Houchins JP, et al.

Immunol Rev. 1989 Oct;111:35-57. Review. No abstract available.

PMID:
2534115
33.

Anti-CD2 monoclonal antibodies and calcium ionophore A23187 modulate lytic activity in CD4+ and CD8+ alloreactive clones.

Inverardi L, Geller RL, Gleason JT, Gromo G.

J Immunol. 1988 May 1;140(9):2876-9.

PMID:
2896214
34.

Minimal signals and step-wise maturation of cytotoxic T cells.

Gromo G, Inverardi L, Geller RL, Schoenheit A, Bach FH.

Transplant Proc. 1988 Apr;20(2):296-7. No abstract available.

PMID:
3259034
35.

Stepwise activation of T cells. Role of the calcium ionophore A23187.

Geller RL, Gromo G, Inverardi L, Ferrero E, Bach FH.

J Immunol. 1987 Dec 15;139(12):3930-4.

PMID:
2826575
36.

Signal requirements in the step-wise functional maturation of cytotoxic T lymphocytes.

Gromo G, Geller RL, Inverardi L, Bach FH.

Nature. 1987 Jun 4-10;327(6121):424-6.

PMID:
3108668
37.

In vitro effects of adenosine induced supernatants on human T lymphocyte functions.

Pardi R, Ferrarini M, Gromo G, Manfredi A, Memoli M, Zocchi MR, Sabbadini MG.

Haematologica. 1987 May-Jun;72(3):215-20. No abstract available.

PMID:
3114086
38.

Long-term growth of lymphokine-activated killer (LAK) cells: role of anti-CD3, beta-IL 1, interferon-gamma and -beta.

Ochoa AC, Gromo G, Alter BJ, Sondel PM, Bach FH.

J Immunol. 1987 Apr 15;138(8):2728-33.

PMID:
2435804
39.

Role of CD2 and IL 1 beta in T cell responsiveness to IL 2.

Gromo G, Geller RL, Inverardi L, Wee SL, Bach FH.

J Immunol. 1987 Apr 1;138(7):2155-60.

PMID:
3104452
40.

Cytotoxic T lymphocytes: blocked differentiation at the 'poised' stage.

Gromo G, Ochoa AC, Bach FH.

Scand J Immunol. 1987 Apr;25(4):383-91.

PMID:
2953065
41.

The stepwise activation of cytotoxic T lymphocytes.

Gromo G, Inverardi L, Geller RL, Alter BJ, Bach FH.

Immunol Today. 1987;8(9):259-61. doi: 10.1016/0167-5699(87)90183-6.

PMID:
25344279
42.

Adenosine induced production of a soluble factor affecting lymphocyte activation.

Zocchi MR, Pardi R, Ferrarini M, Gromo G, Manfredi A, Mosca A, Carpinelli A, Sabbadini MG, Rugarli C.

Immunol Lett. 1986 Oct 15;13(5):245-53.

PMID:
2876953
43.

Regulation of lytic function by recombinant IL2 and antigen.

Ochoa AC, Gromo G, Wee SL, Bach FH.

Curr Top Microbiol Immunol. 1986;126:155-64. No abstract available.

PMID:
2941240
44.

Theophylline induced non specific suppressor activity in human peripheral blood lymphocytes.

Zocchi MR, Pardi R, Gromo G, Ferrero E, Ferrero ME, Besana C, Rugarli C.

J Immunopharmacol. 1985;7(2):217-34.

PMID:
2993422
45.

Fibroplastic endomyocarditis with eosinophilia: presentation of a fatal case and diagnostic considerations on eosinophilic leukemia.

Faravelli A, Gromo G, Besana C.

Haematologica. 1984 Mar-Apr;69(2):218-26. No abstract available.

PMID:
6429007
46.

Spontaneous "in vitro" variations of theophylline sensitivity in human peripheral blood lymphocytes.

Ciboddo GF, Gromo G, Barbieri MC, Crosti F, Ferrero ME, Besana C, Rugarli C.

Boll Ist Sieroter Milan. 1983 May 31;62(2):190-4.

PMID:
6313016
47.

Neuroblastoma in pregnancy.

Besana C, Ciboddo G, Gromo G, Salmaggi C.

Lancet. 1981 Sep 5;2(8245):534. No abstract available.

PMID:
6115287
48.

[Premises and indications for myelography with water-soluble contrast media particularly in lumboischiatic pain].

Ciambellotti E, Gandini G, Imassi GF, Sosso A, Bramante L, Gromo G.

Minerva Med. 1974 Oct 31;65(77):4063-82. Italian. No abstract available.

PMID:
4279361
50.

[Senile osteoporosis and vertebral pathological fractures].

Ceroni P, Gromo G.

G Gerontol. 1969 Feb;17(2):192-205. Italian. No abstract available.

PMID:
5795870

Supplemental Content

Support Center